TIME FOR LIFE

LENALIDOMIDE

  • The first generic product from the family of immunomodulators of signaling pathways of tumor angiogenesis
  • According inretnational guidelines is the first line drug treatment for multiple myeloma, and may also be applied in second line therapy at the development of resistance to bortezomib
  • Use of the drug in the first line of therapy is pharmacoeffective and will increase the overall and disease-free survival